Einat Brill Almon, VP, Product Development at Protalix BioTherapeutics, Inc. (PLX), sold 70,000 shares at $9.02 ($637K) on 2010-10-04, disclosed to the SEC on 2010-10-06.
Scheduled sale ($637k) by VP, Product Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.02 | 35,000 | $316K | 49.6% |
| 2 | $9.08 | 20,000 | $182K | 28.5% |
| 3 | $9.29 | 15,000 | $139K | 21.9% |
| Total | $9.10 avg | 70,000 | $637K | 100% |
| Filing → |
| PLX | SELL | 2009-10-19 | $847K | — | Filing → |
| PLX | SELL | 2009-07-08 | $280K | — | Filing → |
| PLX | SELL | 2009-05-19 | $160K | — | Filing → |